These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 38868124)

  • 21. An Unusual and Rare Presentation of Diffuse Tophaceous Gout.
    Levy-Bedoya RA; Pi Noa D; Dewan A; Tierrablanca S; Strauss NH
    Cureus; 2022 Oct; 14(10):e30121. PubMed ID: 36381907
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Ultrasonography in the diagnosis of asymptomatic hyperuricemia and gout.
    Puig JG; Beltrán LM; Mejía-Chew C; Tevar D; Torres RJ
    Nucleosides Nucleotides Nucleic Acids; 2016 Dec; 35(10-12):517-523. PubMed ID: 27906639
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Management of Gout and Hyperuricemia in CKD.
    Vargas-Santos AB; Neogi T
    Am J Kidney Dis; 2017 Sep; 70(3):422-439. PubMed ID: 28456346
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Use of newly available febuxostat in a case of chronic tophaceous gout contraindicated to allopurinol and probenecid.
    Hilmi BA; Asmahan MI; Rosman A
    Med J Malaysia; 2012 Feb; 67(1):125-6. PubMed ID: 22582566
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Gout: an overview of available urate lowering therapies].
    Richette P
    Ann Pharm Fr; 2012 May; 70(3):133-8. PubMed ID: 22655581
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Urate-oxidase for the treatment of tophaceous gout in heart transplant recipients. A report of three cases.
    Rozenberg S; Roche B; Dorent R; Koeger AC; Borget C; Wrona N; Bourgeois P
    Rev Rhum Engl Ed; 1995 May; 62(5):392-4. PubMed ID: 7655872
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Gout.
    Dalbeth N; Gosling AL; Gaffo A; Abhishek A
    Lancet; 2021 May; 397(10287):1843-1855. PubMed ID: 33798500
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Presence of monosodium urate crystal deposition by dual-energy CT in patients with gout treated with allopurinol.
    Dalbeth N; Nicolaou S; Baumgartner S; Hu J; Fung M; Choi HK
    Ann Rheum Dis; 2018 Mar; 77(3):364-370. PubMed ID: 29146741
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Young Onset Polyarticular Tophaceous Gout: Rare and Aggressive.
    Rana D; Momin ZC
    Cureus; 2021 Aug; 13(8):e16954. PubMed ID: 34513520
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Febuxostat: a novel agent for management of hyperuricemia in gout.
    Bisht M; Bist SS
    Indian J Pharm Sci; 2011 Nov; 73(6):597-600. PubMed ID: 23112391
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical characteristics of and relationship between metabolic components and renal function among patients with early-onset juvenile tophaceous gout.
    Lu CC; Wu SK; Chen HY; Chung WS; Lee MC; Yeh CJ
    J Rheumatol; 2014 Sep; 41(9):1878-83. PubMed ID: 25086077
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Overview of Serum Uric Acid Treatment Targets in Gout: Why Less Than 6 mg/dL?
    Ruoff G; Edwards NL
    Postgrad Med; 2016 Sep; 128(7):706-15. PubMed ID: 27558643
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Disseminated Cutaneous Tophi in a Patient with Chronic Tophaceous Gout and Renal Impairment: A Case Report of a Rare Manifestation of Gout.
    Parlindungan F; Setiyohadi B; Arisanti R
    Am J Case Rep; 2020 Apr; 21():e919349. PubMed ID: 32241962
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Gout and hyperuricemia.
    Chilappa CS; Aronow WS; Shapiro D; Sperber K; Patel U; Ash JY
    Compr Ther; 2010; 36():3-13. PubMed ID: 21229813
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Evaluation of the Relationship Between Serum Urate Levels, Clinical Manifestations of Gout, and Death From Cardiovascular Causes in Patients Receiving Febuxostat or Allopurinol in an Outcomes Trial.
    Saag KG; Becker MA; White WB; Whelton A; Borer JS; Gorelick PB; Hunt B; Castillo M; Gunawardhana L;
    Arthritis Rheumatol; 2022 Sep; 74(9):1593-1601. PubMed ID: 35536764
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Emerging Urate-Lowering Drugs and Pharmacologic Treatment Strategies for Gout: A Narrative Review.
    Terkeltaub R
    Drugs; 2023 Nov; 83(16):1501-1521. PubMed ID: 37819612
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Limitations of the Current Standards of Care for Treating Gout and Crystal Deposition in the Primary Care Setting: A Review.
    Keenan RT
    Clin Ther; 2017 Feb; 39(2):430-441. PubMed ID: 28089200
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Gout Remission as a Goal of Urate-Lowering Therapy: A Critical Review.
    Tabi-Amponsah AD; Stewart S; Hosie G; Stamp LK; Taylor WJ; Dalbeth N
    Pharmaceuticals (Basel); 2023 May; 16(6):. PubMed ID: 37375727
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Febuxostat: a selective xanthine-oxidase/xanthine-dehydrogenase inhibitor for the management of hyperuricemia in adults with gout.
    Ernst ME; Fravel MA
    Clin Ther; 2009 Nov; 31(11):2503-18. PubMed ID: 20109996
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Updates on the treatment of gout, including a review of updated treatment guidelines and use of small molecule therapies for difficult-to-treat gout and gout flares.
    Soskind R; Abazia DT; Bridgeman MB
    Expert Opin Pharmacother; 2017 Aug; 18(11):1115-1125. PubMed ID: 28658988
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.